Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Healthcare AI, Meant to Save Money, Turns Out to Require a Lot of Expensive Humans

2.

When does a melanoma metastasize? Implications for management

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study identifies new target for obesity-related breast cancer

5.

Admissions, medical schools, costs, and eligibility requirements information for FNB Onco-Anesthesia.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot